Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Inhaled bacille Calmette–Guérin (BCG) provides a controlled human model to interrogate anti-mycobacterial immunity at defined time points, something not feasible in natural Mycobacterium tuberculosis infection. It also represents a promising mucosal vaccination route that outperforms intradermal (ID) BCG in animal models. We will present updated findings from two clinical trials in healthy adults: BCG-naïve and historically BCG-vaccinated participants received aerosolised BCG, with control groups of BCG-naïve participants given inhaled saline and previously vaccinated participants given ID BCG. Lung mucosal and peripheral blood responses were characterised longitudinally using single-cell RNA sequencing (scRNA-seq) and bulk T-cell receptor (TCR) sequencing.
